Skip to main content

Table 3 Impact of MetS components on coronary collateral growth in patients with and without MetS

From: Metabolic syndrome and its components reduce coronary collateralization in chronic total occlusion: An observational study

Variables

Quartiles of components

Non-MetS

MetS

All

Range

n

Good/Poor

OR (95%CI)

P Value

Good/Poor

OR (95%CI)

P Value

Good/Poor

OR (95%CI)

P Value

HT, n(%)

–

1071

73/319

1.386 (0.758–2.534)

0.289

182/497

1.478 (0.881–2.481)

0.139

255/816

1.179 (0.818–1.699)

0.377

T2DM, n(%)

–

570

38/129

2.292 (0.886–5.929)

0.087

118/285

1.718 (0.988–2.987)

0.055

156/414

1.664 (1.053–2.629)

0.029

BMI, Kg/m2

Per quartile

1653

140/672

1.897 (1.458–2.467)

 < 0.001

230/667

1.814 (1.482–2.220)

 < 0.001

370/1339

1.755 (1.510–2.038)

 < 0.001

 

Q1 ≤ 24.33

412

19/225

–

–

21/137

–

–

40/362

–

–

 

24.33 < Q2 ≤ 26.29

415

30/187

6.413 (2.679–15.354)

 < 0.001

30/168

5.424 (2.688–10.943)

 < 0.001

60/355

4.852 (2.934–8.024)

 < 0.001

 

26.29 < Q3 ≤ 28.37

413

54/164

4.330 (1.952–9.604)

 < 0.001

54/141

4.399 (2.467–7.844)

 < 0.001

108/305

3.594 (2.324–5.560)

 < 0.001

 

28.37 < Q4

413

30/72

1.720 (0.847–3.490)

0.133

117/194

1.768 (1.085–2.940)

0.023

147/266

1.464 (1.010–2.121)

0.044

TG, mmol/L

Per quartile

1653

 

1.664 (1.264–2.190)

 < 0.001

 

1.407 (1.136–1.744)

0.002

370/1339

1.371 (1.184–1.588)

 < 0.001

 

Q1 ≤ 1.08

412

30/275

–

–

20/87

–

–

50/362

–

–

 

1.09 < Q2 ≤ 1.44

421

57/225

5.940 (2.203–16.012)

 < 0.001

28/111

2.324 (1.097–4.927)

0.028

85/336

2.764 (1.694–4.510)

 < 0.001

 

1.44 < Q3 ≤ 2.07

410

30/119

2.093 (0.822–5.311)

0.121

71/190

2.750 (1.422–5.320)

0.003

101/309

1.609 (1.040–2.491)

0.033

 

2.07 < Q4

410

16/39

2.087 (0.806–5.400)

0.129

103/252

1.149 (0.727–1.816)

0.551

119/291

1.161 (0.790–1.706)

0.447

HDL-C, mmol/L

Per quartile

1653

 

0.970 (0.751–1.252)

0.812

 

0.918 (0.741–1.137)

0.431

370/1339

1.006 (0.866–1.168)

0.937

 

Q1 ≤ 0.84

414

20/85

–

–

83/226

–

–

103/311

–

–

 

0.84<Q2≤0.98

408

21/99

0.893 (0.396–2.015)

0.786

69/219

0.751 (0.345–1.631)

0.469

90/318

1.092 (0.679–1.756)

0.715

 

0.98<Q3 ≤ 1.16

412

38/194

1.179 (0.524–2.651)

0.691

45/135

0.882 (0.407–1.912)

0.751

83/329

1.241 (0.775–1.989)

0.368

 

1.16<Q4

419

54/280

1.558 (0.794–3.055)

0.197

25/60

0.938 (0.416–2.114)

0.877

79/340

1.223 (0.761–1.965)

0.406

SBP, mmHg

Per quartile

1653

 

1.162 (0.858–1573)

0.333

 

1.362 (1.078–1.720)

0.010

370/1339

1.252 (1.049–1.496)

0.013

 

Q1 ≤ 119

425

32/199

–

–

31/163

-

–

63/362

–

–

 

119<Q2≤128

412

39/181

1.715 (0.631–4.664)

0.290

38/154

2.438 (1.140–5.215)

0.022

77/335

1.975 (1.121–3.478)

0.019

 

128<Q3 ≤ 137

400

29/148

1.215 (0.519–2.844)

0.653

62/161

1.915 (1.016–3.610)

0.044

91/309

1.601 (0994–2.579)

0.053

 

137<Q4

416

33/130

1.270 (0.546–2.956)

0.579

91/162

1.215 (0.712–2.072)

0.475

124/292

1.319 (0.862–2.019)

0.202

DBP, mmHg

Per quartile

1653

 

1.089 (0.806–1.471)

0.579

 

1.287 (1.024–1.617)

0.030

370/1339

1.202 (1.010–1.430)

0.038

 

Q1 ≤ 69

381

27/168

–

–

37/149

–

–

64/317

–

–

 

69<Q2≤75

424

37/191

1.439 (0.531–3.901)

0.640

37/159

1.905 (0.939–3.865)

0.074

74/350

1.769 (1.029–3.044)

0.039

 

75<Q3 ≤ 82

417

33/178

1.630 (0.692–3.838)

0.288

45/161

2.711 (1.437–5.135)

0.002

78/339

1.967 (1.230–3.146)

0.005

 

82<Q4

431

36/121

1.848 (0.796–4.292)

0.153

103/171

2.794 (1.573–4.963)

 < 0.001

139/292

2.215 (1.415–3.465)

 < 0.001

FBG, mmol/L

Per quartile

1709

 

1.018 (0.735–1.409)

0.917

 

1.006 (0.817–1.238)

0.955

370/1339

0.968 (0.825–1.136)

0.691

 

Q1 ≤ 5.12

420

47/233

–

–

36/104

–

–

83/337

–

 
 

5.12<Q2≤5.76

410

38/244

1.505 (0.499–4.542)

0.468

27/101

1.047 (0.540–2.029)

0.892

65/345

0.922 (0.565–1.505)

0.745

 

5.76<Q3 ≤ 7.33

411

22/101

2.354 (0.745–7.442)

0.145

68/220

1.193 (0.614–2.320)

0.603

90/321

1.305 (0.787–2.163)

0.302

 

7.33<Q4

412

26/80

1.654 (0.577–4.745)

0.349

91/215

1.042 (0.628–1.730)

0.873

117/295

1.156 (0.748–1.786)

0.514

  1. OR odds ratio, CIconfdence interval, MetS Metabolic Syndrome, BMI body mass index, HT Hypertension, T2DM type 2 diabetes mellitus, HDL-C high-density lipoprotein cholesterol, TG Triglycerides, FBG Fasting blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure
  2. aMultiple adjustment for adjusted for age, sex, heart rate, renal disease, former smoker, current smoker, prior myocardial infarction, stroke, history of percutaneous coronary intervention, white blood cell, homocysteine, platelet, creatinine, eGFR, glycated albumin, uric acid, ventricular ejection fraction; left ventricular end-diastolic dimension; left ventricular end-systolic dimension, Diuretics, ACE inhibitors/ARBs,β-blockers, CCBs, hypoglycemic agents
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840